Clinical Trials
13 trialsNCT04862663 2026-05-27
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT07237256 2026-05-26
NoLEEta
UNICANCER
Phase 3 Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07492641 2026-05-22
KANDELA-302
BeOne Medicines
Phase 3 Recruiting
NCT06760637 2026-05-19
FourLight-3
Pfizer
Phase 3 Active not recruiting
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT07085767 2026-05-15
OPERA-02
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT05827081 2026-05-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06377852 2026-05-13
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT07391774 2026-05-13
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
National Cancer Institute (NCI)
Phase 3 Not yet recruiting
NCT04055493 2026-05-11
ADAPTcycle
West German Study Group
Phase 3 Active not recruiting
NCT06065748 2026-05-05
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting